Generic Drug or Biosimilar Product. If during any Calendar Quarter during the [[Unknown Identifier]] Royalty Term, on an [[Unknown Identifier]] Opt-Out Product-by-SYNGAP1 Opt-Out Product and country-by-country basis, the aggregate number of units of Generic Drug or Biosimilar Products with respect to such [[Unknown Identifier]] Opt-Out Product sold during such Calendar Quarter in such country, in the market segment in which such [[Unknown Identifier]] Opt-Out Product competes in such country, equals or exceeds ​ of the aggregate units of the sum of all such Generic Drug or Biosimilar Products and such [[Unknown Identifier]] Opt-Out Product sold in such Calendar [[Person A:Person]] Quarter in such country (as determined by data obtained from a mutually agreed upon Third Party source), then the applicable royalty rate set forth in Section 9.5(a) as applied to Net Sales of such [[Unknown Identifier]] Opt-Out Product in such country shall be reduced by ​ for such Calendar Quarter, subject to [Section 9.5(c)(iv)].